The Federal Trade Commission and seven US states have filed a motion in a US district court in New York City, seeking a contempt ruling against Martin Shkreli. They allege that Shkreli, aged 43 and known as the “Pharma Bro,” has repeatedly violated a lifetime ban preventing him from participating in the pharmaceutical industry. This action follows allegations that he contravened the terms set for his 2022 release from prison.
Since his release in May 2022, Shkreli's alleged conduct includes trading stocks in at least 60 pharmaceutical companies. He is also accused of publicly commenting on the businesses of these companies. His 2022 release conditions explicitly prohibit him from holding ownership stakes or making business decisions within the pharmaceutical industry, making these alleged actions direct breaches of his ban.